Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CAM Use In Minority Populations Research To Be Funded By NCCAM

This article was originally published in The Tan Sheet

Executive Summary

NCCAM-funded studies of minority populations' use of complementary and alternative medicine could include epidemiological, health services and outcomes research, an April 11 program announcement states

You may also be interested in...

Minorities' CAM Use Research Gaps To Be Identified In NCCAM Workshop

An NCCAM workshop to identify challenges of conducting research on complementary and alternative medicine use in "culturally diverse populations" is outlined in the center's recently released Strategic Plan to Address Racial and Ethnic Health Disparities.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts